Thermo Fisher delivered strong Q1 results, beating expectations with revenue of $12.21B (+7% YoY) and EPS of $6.57 (+8%). I reaffirm my strong buy rating on TMO, setting a target price of $668 per share, citing resilient margins and competitive positioning. TMO's 2026 guidance calls for $46.3B-$47.2B revenue (+4-6%) and EPS of $24.22-$24.80 (+6-8%), with organic growth of 4%.
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) delivered a fourth quarter earnings beat, but its shares moved lower as investors focused on margin pressures and cautious earnings guidance for 2026. The life sciences tools and diagnostics company guided 2026 revenue to a range of $46.3 billion to $47.2 billion, implying 4% to 6% growth and organic growth of 3% to 4%, broadly in line with consensus expectations and indicating continued modest demand across biopharma and life sciences end markets.
| Professional Services Industry | Industrials Sector | Marc N. Casper CEO | XMEX Exchange | US8835561023 ISIN |
| US Country | 125,000 Employees | 15 Dec 2025 Last Dividend | 6 Jun 1996 Last Split | 13 Jan 1978 IPO Date |
Thermo Fisher Scientific Inc. is a global leader in serving science, offering a wide range of products and services across life sciences, analytical instruments, specialty diagnostics, and laboratory products, as well as biopharma services. The company boasts a broad presence, serving customers in North America, Europe, the Asia-Pacific region, and internationally. Its offerings are designed to cater to the needs of the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. By delivering solutions that support research and development, diagnostics, and the production of drugs and vaccines, Thermo Fisher Scientific plays a pivotal role in advancing public health and scientific endeavors worldwide. Founded in 1956, the company is headquartered in Waltham, Massachusetts.
This segment provides a variety of reagents, instruments, and consumables used in biological and medical research, the discovery and production of drugs and vaccines, and the diagnosis of infections and diseases. The offerings encompass biosciences, genetic sciences, and bio production and are tailored for markets including pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government sectors.
Includes instruments, consumables, software, and services suited for a wide range of applications in the pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. These instruments and services facilitate complex analyses and experiments.
This segment offers a variety of diagnostic products and services, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments. It covers the needs of the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; provides human leukocyte antigen typing and testing for the organ transplant market; and supplies healthcare products.
Provides an extensive array of laboratory products and services, including research and safety market channel and pharma services and clinical research, catering to various scientific needs. The segment supports the research, development, and production processes across the scientific community.
The company offers these products and services through a combined approach of a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon and PPD brands.